Status | Study |
Not yet recruiting |
Study Name: Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet Condition: Cold Hypersensitivity Date: 2017-03-14 Interventions: Drug: Ojeok-San Usage: 3g, thr |
Terminated |
Study Name: HL2351 CAPS Phase II Study Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS) Date: 2016-05-10 Interventions: Drug: HL2351 The dose will be adjusted based on disease activities |
Recruiting |
Study Name: Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Condition: Cold Hypersensitivity Date: 2015-12-30 Interventions: Drug: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang |
Completed |
Study Name: Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet Condition: Cold Hypersensitivity Date: 2012-08-08 Interventions: Drug: Korean red ginseng Korea |
Completed |
Study Name: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Date: 2012-02-17 Interventions: Drug: ACZ885 |
Completed |
Study Name: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients Condition: Cryopyrin-associated Periodic Syndromes (CAPS) Familial Cold Autoinflam Syn (FCAS) Date: 2010-09-30 |
Withdrawn |
Study Name: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Condition: Muckle Wells Syndrome Autoinflammatory Behcet's Disease Date: 2010-09-29 Interventions: Drug: XOMA 052 |
Completed |
Study Name: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Condition: Cryopyrin Associated Periodic Syndrome Date: 2010-03-25 Interventions: Drug: canakinumab (company code: ACZ885D) |
Completed |
Study Name: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Date: 2009-10-06 Interventions: Drug: canakinumab canakinumab |
Completed |
Study Name: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition: Cryopyrin-Associated Periodic Syndromes Familial Cold Autoinflammatory Date: 2008-05-27 Interventions: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |